Dublin headquartered medical devices firm Biotrin has signed a €7.6 million deal to buy technologies that will drive its molecular diagnostics business.

Founded in 1992, the company, which was bought by the Italian DiaSorin group in 2008, develops technologies to run diagnostic tests for common infectious diseases.

Yesterday, Biotrin announced it had concluded a deal with Norwegian company NorDiag ASA for the acquisition of its technologies related to the extraction of nucleic acids, including DNA, used in molecular diagnostic applications.

NorDiag’s molecular business unit last year yielded €4 million in revenues from products including kits for the extraction of DNA from blood and urine samples.

Commenting on the agreement, chief executive of DiaSorin, Carlo Rosso, said the acquisition would position the company “as a reliable and credible player in the rapidly expanding segment of molecular diagnostics”.

The deal was financed entirely through the internal resources of the company. Biotrin employs 100 people at its Dublin facility.